2018
P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab
Pentsova E, Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Boire A, DeAngelis L, Raizer J. P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab. Neuro-Oncology 2018, 20: iii304-iii304. PMCID: PMC6144227, DOI: 10.1093/neuonc/noy139.336.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemCTC enumerationCSF cytologyTreatment responsePhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentHER2-positive cancersCycle 1Number of CTCsIntrathecal trastuzumabIT trastuzumabLM progressionEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningProspective evaluationPositive cancersHER2 expressionCerebrospinal fluid
2017
CMET-04. CEREBROSPINAL FLUID CIRCULATING TUMOR CELLS (CSF CTC) FOR PATIENT MONITORING AND RESPONSE TO TREATMENT
Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. CMET-04. CEREBROSPINAL FLUID CIRCULATING TUMOR CELLS (CSF CTC) FOR PATIENT MONITORING AND RESPONSE TO TREATMENT. Neuro-Oncology 2017, 19: vi39-vi39. PMCID: PMC5692986, DOI: 10.1093/neuonc/nox168.153.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCTC enumerationLM progressionCellSearch systemHER2 expressionTreatment responsePhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentNumber of CTCsCycle 1IT trastuzumabCirculating Tumor CellsEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningCSF cytologyEarly biomarkersHER2 analysisPatientsDay 1Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.
Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. Journal Of Clinical Oncology 2017, 35: 11549-11549. DOI: 10.1200/jco.2017.35.15_suppl.11549.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemTreatment responseCTC enumerationLM progressionCSF cytologyPhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentCycle 1IT trastuzumabEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningDisease progressionEarly biomarkersCerebrospinal fluidDay 1Colon cancerPotential biomarkersDiagnostic marker
2012
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study